Company News-Bio-Thera Solutions, Ltd.

STADA and Bio-Thera receive European Marketing Authorization for Gotenfia, a Biosimilar to Simponi

2026-02-13

• European Commission grants approval for Gotenfia®, a golimumab biosimilar to Simponi® that was developed by Bio-Thera ...

查看详情

09-112024

Bio-Thera Solutions and Biogen Publish Phase 3 Clinical Trial Data for TOFIDENCETM (BAT1806/BIIB800), an approved Biosimilar referencing tocilizumab in Arthritis Research & Therapy

Comparable clinical efficacy and safety in Treatment Period 2 (TP2, Week 24-48) is maintained after switch from referenc...
08-162024

Bio-Thera Solutions and Pharmapark Further Expand Partnership in Russia and other CIS Countries with Addition of BAT2306, a Cosentyx® Biosimilar

GUANGZHOU, China and MOSCOW, Russia --- Bio-Thera Solutions, Ltd (688177:SH), a commercial-stagebiopharmaceutical compan...
07-302024

European Medicines Agency (EMA) Approves Bio-Thera Solutions’ BAT1706 (Avzivi®, bevacizumab), a biosimilar referencing Avastin®

BAT1706 is Bio-Thera Solutions’ second EMAapproved product BAT1706 is Bio-Thera Solutions’ secondproduct receiving marke...

上一页 ···8 9 10 11 12 ··· 下一页